Creo Medical GroupCMEOF 52 PS Ratio is 10.53 as of Jul. 02, 2026, which is 2% above its 10-year median of 10.36. GuruFocus rates CMEOF with a GF Score™ of 52/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 84.58% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Creo Medical Group's share price is $0.20.
Creo Medical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02. Hence, Creo Medical Group's PS Ratio for today is 10.53.
The historical rank and industry rank for Creo Medical Group's PS Ratio or its related term are showing as below:
CMEOF'
s PS Ratio Range Over the Past 10 Years
Min: 1.27 Med: 10.36 Max: 37.24
Current: 9.64
During the past 11 years, Creo Medical Group's highest PS Ratio was 37.24. The lowest was 1.27. And the median was 10.36.
CMEOF's PS Ratio is ranked worse than 84.58% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.925
vs CMEOF: 9.64
Creo Medical Group PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Creo Medical Group was 27.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -54.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -39.00% per year.
During the past 11 years, Creo Medical Group's highest 3-Year average Revenue per Share Growth Rate was -39.30% per year. The lowest was -58.00% per year. And the median was -54.10% per year.
Back to Basics: PS Ratio
Creo Medical Group (OTCPK:CMEOF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Creo Medical Group PS Ratio Related Terms
Creo Medical Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Creo Medical Group's Share Price of today is $0.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Creo Medical Group (CMEOF) has a PS Ratio of 10.53 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Creo Medical Group and its competitors. This is near median its historical median of 10.36. Over the past decade, Creo Medical Group's PS Ratio has ranged from 1.27 to 37.24. According to the industry distribution chart, Creo Medical Group ranks #680 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 84.6%.
Is Creo Medical Group's PS Ratio too high?
Creo Medical Group's current PS Ratio of 10.53 is near median its 10-year median of 10.36. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 37.24. The Medical Devices & Instruments industry median PS Ratio is 2.93. Creo Medical Group's value of 10.53 is 260% above this industry median. Based on the distribution chart, Creo Medical Group ranks #680 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #680 out of 804 companies for PS Ratio. This places Creo Medical Group in the lower half of its industry. The industry median PS Ratio is 2.93. Creo Medical Group's value of 10.53 is 260% above this benchmark. Historically, Creo Medical Group's own PS Ratio has ranged from 1.27 to 37.24 over the past decade. While the company's 10-year median is 10.36 vs. the industry median of 2.93, Creo Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.93, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current PS Ratio of 10.53 is 260% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current PS Ratio is 10.53, which is near median its own 10-year median of 10.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current PS Ratio of 10.53. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current PS Ratio is 10.53, which is near median its 10-year median of 10.36 and 260% above the Medical Devices & Instruments industry median of 2.93. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current PS Ratio is 10.53 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
PS Ratio: 10.53 (near median its 10-year median of 10.36)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
Industry Position: 260% above the Medical Devices & Instruments median (#680 of 804)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for CMEOF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
